UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/661,912	09/12/2003	James P. Gardner JR.	74074 - 365307	8343	
43546 FAEGRE & BE	7590 08/07/200 ENSON	EXAMINER			
ATTN: PATENT DOCKETING			LEVY, NEIL S		
	2200 WELLS FARGO CENTER 90 SOUTH SEVENTH STREET		ART UNIT	PAPER NUMBER	
MINNEAPOLI	MINNEAPOLIS, MN 55402-3901			1615	
			MAIL DATE	DELIVERY MODE	
			08/07/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Occurrence	10/661,912	GARDNER ET AL.				
Office Action Summary	Examiner	Art Unit				
	NEIL LEVY	1615				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1)⊠ Responsive to communication(s) filed on <u>29 Ju</u>	lv 2008.					
	action is non-final.					
<i>,</i> —	, 					
closed in accordance with the practice under E						
Disposition of Claims						
4)⊠ Claim(s) <u>1-9,12,15-19,24-30,41-46 and 53</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-9,12,15-19,24-30,41-46,53</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-9,12,15-19,24-30,41-46 and 53</u> are	subject to restriction and/or elect	ion requirement.				
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) acce		Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1.☐ Certified copies of the priority documents have been received.						
	_					
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).						
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
1) X Notice of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) DNotice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate				
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal P 6) Other:	atent Application				
apor rolo/main bate	o/					

Application/Control Number: 10/661,912 Page 2

Art Unit: 1615

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

.Note that boric acid, not Mg nanoparticles, is the elected stabilizer.

Claim Rejections - 35 USC § 102

Claim1,3,5, 7, 12, 16, 17, 41-44, 46 and 53 STAND rejected under 35

U.S.C. 102(b) as being anticipated BARCAY eT al 5820855.

The base baits & 5-50% fat, shown as a stabilizer for the water sensitive insecticides, inclusive of the soluble boric acid, meet the instant composition claims, whether used for the same purpose or not.

Claim1,3-5, 7, 9, 12, 13, 16-19, 46 & 53 stand rejected under 35 U.S.C. 102(b) as being anticipated HONSYU et al CN1155978.

Stabilizer can be considered to be the gelling agent, @ 0-50% (p. 3, # 4). Mixing is at claim 9. Acephate is at claim 3, attractant at claim 4. The high toxicity (page 3) is provided by the formulation, that of the instant as claimed, so, inherently, of the same claimed results-100% death resulted after 72 hours (Table 3) for cockroach.

Claim Rejections - 35 USC § 103

Claim1-9,12,15 -19,24-29, 41, 42, 46 & 53 stand rejected under 35 U.S.C.

103(a) as being unpatentable over DYKSTRA et al WO 91/07972 in view of Twydell

US006861075B2

DYKSTRA: See claim 2-baits include feeding stimulants and attractants (page 5) and humectants to retain water (50% in Example, page 6) included are protein, oil, and molasses (page 5). Mortality was more than 50% in 1 day, and 95% at 72 hours, thus meeting the instant claims, if cockroach is the insect. Boric acid (Example 1) is 5% acephate is used at 0.5% (Example 3) thus obvious to combine at these rates, when combination (page 5, lines 8, 9, claim 2) are used.

Twydell; Gel baits are made here too, see exmple 3; a sufficient amount of boric acid is used to meet the instant claimed stabilizer-

Page 3

It would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to utilize pest control means, to use any of art recognized means, as of the Dykstra acephate/boric acid baits modified as desired to increase stability, dispersibility, compatability of ingredients, processing ease, reduced toxicity to handlers& increased effectiveness by increasing the amount of boric acid, as shown possible by Twydell.

The amounts and proportions of each ingredient are result effective parameters chosen to obtain the desired effects. It would be obvious to vary the form of each ingredient to optimize the effect desired, depending upon the particular species and application method of interest, reduction of toxicity, cost minimization, enhanced, and prolonged, or synergistic effects.

Applicant has not provided any objective evidence of criticality, nonobvious or unexpected results that the administration of the particular ingredients' or concentrations provides any greater or different level of prior art expectation as claimed, and the use of ingredient for the functionality for which they are known to be used is not basis for patentability.

The instant invention provides well known old art recognized compounds, with well known art recognized effects, applied by well known art recognized methods to achieve improved control as is well known in the art.

Double Patenting

Claim1-9, 12, 15-19, 24-29, 41, 42, 53 stand. rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim1-11 of U.S. Patent No. 7192600. Although the conflicting claims are not identical, they are not patentably distinct from each other because for reason of record.

Response to Arguments

Applicant's arguments filed 7/29/08 have been fully considered but they are not persuasiveArguments are addressed above, in essence, the stabilizer is argued to not be so stated in the references- examiner finds, absent specifying the desired stabilizer, anything construed to provide some kind of stabilization or other in fact meets the claim language.

The double patenting rejection over 5820855 is withdrawn, as is the anticipation over Dykstra.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Application/Control Number: 10/661,912 Page 5

Art Unit: 1615

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM EST..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, MICHAEL WOODWARD can be reached on 571-272-8373. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/661,912 Page 6

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NEIL LEVY/ Primary Examiner, Art Unit 1615
